India’s anti-obesity pharmaceutical market surged to Rs 628 crore as per the moving annual total (MAT) ending June 2025, a fivefold increase over five years with a 46 percent CAGR, making it the fastest-growing therapeutic segment in the Indian pharma landscape, according to market research firm PharmaTrac.
The growth was led by GLP-1 receptor agonists, notably Semaglutide and Tirzepatide, which together command 75 percent of the market by value.
Rybelsus, the oral form of Semaglutide launched by Novo Nordisk in January 2022, has grown from Rs 26 crore to Rs 412 crore, capturing a 66 percent market share.
Mounjaro, the Tirzepatide-based drug from Eli Lilly launched in March 2025, has reached Rs 50 crore in value and captured an 8 percent market share within one quarter.
Mounjaro’s uptake has been rapid, with sales rising from 11,637 units in March to 87,986 in June 2025. Of these, 39,042 units were the 2.5 mg starting dose, and the rest were 5 mg, indicating strong adherence and new patient onboarding.
Wegovy off to a good start
Wegovy, the injectable form of Semaglutide launched in June 2025, sold 1,788 units worth Rs 2.53 crore across five strengths — indicating prior patient familiarity through imported versions.
GLP-1 drugs represent a shift from older agents like Orlistat, which targeted fat absorption. These newer drugs suppress appetite and slow gastric emptying, aligning better with India’s carb-rich diets and promoting sustainable weight loss.
The broader Indian Pharmaceutical Market (IPM) posted 7.68 percent value growth in Q1 FY26, with June 2025 alone contributing 8 percent, driven by price growth (5.3 percent) and new product launches (2.4 percent). Volume growth for the month stood at 1.6 percent, with therapies like Respiratory and Anti-Infectives gaining traction as monsoon began.
Top pharma players showed strong performance, with Alkem’s Pan topping monthly sales while Augmentin and Glycomet GP maintained their annual leadership positions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
